GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Debt-to-Asset

Estrella Immunopharma (Estrella Immunopharma) Debt-to-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Debt-to-Asset?

Estrella Immunopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Estrella Immunopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Estrella Immunopharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $8.63 Mil. Estrella Immunopharma's debt to asset for the quarter that ended in Mar. 2024 was 0.00.


Estrella Immunopharma Debt-to-Asset Historical Data

The historical data trend for Estrella Immunopharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Debt-to-Asset Chart

Estrella Immunopharma Annual Data
Trend Jun21
Debt-to-Asset
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 - 0.01 - -

Competitive Comparison of Estrella Immunopharma's Debt-to-Asset

For the Biotechnology subindustry, Estrella Immunopharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Estrella Immunopharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's Debt-to-Asset falls into.



Estrella Immunopharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Estrella Immunopharma's Debt-to-Asset for the fiscal year that ended in Jun. 2021 is calculated as

Estrella Immunopharma's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Estrella Immunopharma  (NAS:ESLA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Estrella Immunopharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma (Estrella Immunopharma) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines